Denali Therapeutics Inc. $DNLI Shares Purchased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D increased its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 47.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 137,880 shares of the company’s stock after acquiring an additional 44,290 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.09% of Denali Therapeutics worth $1,929,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd boosted its holdings in Denali Therapeutics by 277.0% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,111 shares of the company’s stock valued at $29,000 after purchasing an additional 1,551 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Denali Therapeutics in the 1st quarter worth approximately $41,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company’s stock worth $79,000 after acquiring an additional 753 shares during the last quarter. Entropy Technologies LP acquired a new position in shares of Denali Therapeutics in the 1st quarter worth approximately $152,000. Finally, E Fund Management Co. Ltd. increased its stake in Denali Therapeutics by 20.7% during the 1st quarter. E Fund Management Co. Ltd. now owns 12,069 shares of the company’s stock worth $164,000 after buying an additional 2,072 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Trading Down 0.6%

NASDAQ DNLI opened at $16.28 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.27 and a quick ratio of 10.27. The firm’s fifty day moving average price is $15.14 and its 200 day moving average price is $14.61. The company has a market capitalization of $2.38 billion, a price-to-earnings ratio of -5.81 and a beta of 1.30. Denali Therapeutics Inc. has a 12 month low of $10.57 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.02. During the same period in the previous year, the business posted ($0.59) EPS. On average, sell-side analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

DNLI has been the topic of several recent research reports. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Monday, July 28th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Denali Therapeutics in a research report on Monday, September 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Finally, Morgan Stanley cut their price objective on Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, August 18th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $32.45.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,937 shares of Denali Therapeutics stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the transaction, the insider directly owned 242,346 shares in the company, valued at approximately $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Carole Ho sold 2,937 shares of Denali Therapeutics stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the transaction, the insider owned 217,391 shares in the company, valued at approximately $2,952,169.78. This represents a 1.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 6,680 shares of company stock worth $91,569. 12.50% of the stock is currently owned by company insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.